NC6 3.85% 2.5¢ nanollose limited

Not to mention the expectation of commercial supply of...

  1. 377 Posts.
    lightbulb Created with Sketch. 307
    Not to mention the expectation of commercial supply of Jelli-Grow in mid-2023.
    I think it's interesting in the Cash Flow sheet that they've only got 1.85 quarters of funding remaining, and have not said that they're planning on a cash raise but instead "the company is confident it will have access to sufficient capital when needed".

    R&D tax rebate due soon, second pilot spin with some sales by end of Feb/early March.
    Their R&D spend is relatively low compared to other biotechs, which also means their rebate won't be a big payday. It's going to be dependent on the revenue of the next pilot spin sales whether they will need to do a cash raise by the next quarter.
 
watchlist Created with Sketch. Add NC6 (ASX) to my watchlist
(20min delay)
Last
2.5¢
Change
-0.001(3.85%)
Mkt cap ! $4.3M
Open High Low Value Volume
2.5¢ 2.6¢ 2.5¢ $11.9K 475K

Buyers (Bids)

No. Vol. Price($)
1 41666 2.4¢
 

Sellers (Offers)

Price($) Vol. No.
2.6¢ 145635 1
View Market Depth
Last trade - 13.52pm 28/06/2024 (20 minute delay) ?
NC6 (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.